Emergent Biosolutions Current Ratio 2007-2021 | EBS

Emergent Biosolutions current ratio from 2007 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Emergent Biosolutions Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $1.16B $0.38B 3.08
2021-03-31 $1.18B $0.37B 3.19
2020-12-31 $1.20B $0.39B 3.11
2020-09-30 $0.96B $0.30B 3.20
2020-06-30 $0.80B $0.29B 2.71
2020-03-31 $0.63B $0.21B 3.03
2019-12-31 $0.69B $0.22B 3.17
2019-09-30 $0.70B $0.28B 2.54
2019-06-30 $0.69B $0.30B 2.30
2019-03-31 $0.53B $0.25B 2.13
2018-12-31 $0.62B $0.20B 3.10
2018-09-30 $0.56B $0.10B 5.52
2018-06-30 $0.54B $0.10B 5.59
2018-03-31 $0.48B $0.09B 5.49
2017-12-31 $0.49B $0.10B 4.85
2017-09-30 $0.56B $0.08B 7.37
2017-06-30 $0.51B $0.07B 6.99
2017-03-31 $0.49B $0.07B 7.23
2016-12-31 $0.51B $0.11B 4.82
2016-09-30 $0.48B $0.11B 4.35
2016-06-30 $0.53B $0.10B 5.08
2016-03-31 $0.53B $0.09B 5.84
2015-12-31 $0.54B $0.10B 5.40
2015-09-30 $0.47B $0.09B 5.34
2015-06-30 $0.44B $0.09B 5.01
2015-03-31 $0.41B $0.08B 5.05
2014-12-31 $0.43B $0.09B 4.65
2014-09-30 $0.38B $0.08B 4.71
2014-06-30 $0.35B $0.08B 4.52
2014-03-31 $0.33B $0.07B 4.52
2013-12-31 $0.27B $0.06B 4.82
2013-09-30 $0.23B $0.06B 4.13
2013-06-30 $0.25B $0.05B 5.09
2013-03-31 $0.24B $0.04B 5.45
2012-12-31 $0.26B $0.06B 4.25
2012-09-30 $0.25B $0.05B 5.00
2012-06-30 $0.24B $0.04B 5.47
2012-03-31 $0.24B $0.04B 5.57
2011-12-31 $0.25B $0.07B 3.58
2011-09-30 $0.24B $0.07B 3.44
2011-06-30 $0.22B $0.07B 3.09
2011-03-31 $0.22B $0.07B 3.05
2010-12-31 $0.24B $0.08B 3.22
2010-09-30 $0.21B $0.05B 4.23
2010-06-30 $0.19B $0.05B 4.28
2010-03-31 $0.19B $0.05B 3.98
2009-12-31 $0.19B $0.06B 3.54
2009-09-30 $0.20B $0.06B 3.41
2009-06-30 $0.20B $0.07B 2.79
2009-03-31 $0.16B $0.05B 3.02
2008-12-31 $0.15B $0.05B 2.83
2008-09-30 $0.15B $0.05B 2.95
2008-06-30 $0.14B $0.05B 2.67
2008-03-31 $0.14B $0.05B 2.83
2007-12-31 $0.14B $0.06B 2.59
2007-09-30 $0.11B $0.04B 3.02
2007-06-30 $0.10B $0.03B 3.09
2007-03-31 $0.10B $0.03B 3.40
2006-12-31 $0.15B $0.06B 2.29
2006-09-30 $0.00B 0.00
2006-06-30 $0.00B 0.00
2006-03-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.717B $1.555B
Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining the trust of their customers, employees and shareholders. The foundation of the corporate governance principles and practices are built on their reputation for openness, integrity and accountability. These are the principles that guide Emergent BioSolutions everyday. They have in place policies and practices to ensure that their Company is managed with integrity and in their shareholders' best interests. In addition, they are committed to meeting the requirements of federal and state law and the rules of the New York Stock Exchange.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57